Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2004-09-07
2010-02-23
Sajjadi, Fereydoun G (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S320100, C514S04400A
Reexamination Certificate
active
07666405
ABSTRACT:
The present invention provides deleted adenovirus vectors. The inventive adenovirus vectors carry one or more deletions in the IVa2, 100K, polymerase and/or preterminal protein sequences of the adenovirus genome. The adenoviruses may additionally contain other deletions, mutations or other modifications as well. In particular preferred embodiments, the adenovirus genome is multiply deleted, i.e., carries two or more deletions therein. The deleted adenoviruses of the invention are “propagation-defective” in that the virus cannot replicate and produce new virions in the absence of complementing function(s). Preferred adenovirus vectors of the invention carry a heterologous nucleotide sequence encoding a protein or peptide associated with a metabolic disorder, more preferably a protein or peptide associated with a lysosomal or glycogen storage disease, most preferably, a lysosomal acid α-glucosidase. Further provided are methods for producing the inventive deleted adenovirus vectors. Further provided are methods of administering the deleted adenovirus vectors to a cell in vitro or in vivo.
REFERENCES:
patent: 5354678 (1994-10-01), Lebkowski et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5518913 (1996-05-01), Massie et al.
patent: 5585362 (1996-12-01), Wilson et al.
patent: 5670488 (1997-09-01), Gregory et al.
patent: 5674722 (1997-10-01), Mulligan et al.
patent: 5700470 (1997-12-01), Saito et al.
patent: 5707618 (1998-01-01), Armentano et al.
patent: 5731172 (1998-03-01), Saito et al.
patent: 5824544 (1998-10-01), Armentano et al.
patent: 5837511 (1998-11-01), Falck-Pedersen et al.
patent: 5849561 (1998-12-01), Falck-Pedersen
patent: 5851806 (1998-12-01), Kovesdi et al.
patent: 5877011 (1999-03-01), Armentano et al.
patent: 5880102 (1999-03-01), George et al.
patent: 5882877 (1999-03-01), Gregory et al.
patent: 5891690 (1999-04-01), Massie
patent: 5919676 (1999-07-01), Graham et al.
patent: 5922576 (1999-07-01), He et al.
patent: 5928944 (1999-07-01), Seth et al.
patent: 5980886 (1999-11-01), Kay et al.
patent: 5981225 (1999-11-01), Kochanek et al.
patent: 5981275 (1999-11-01), Armentano et al.
patent: 5994106 (1999-11-01), Kovesdi et al.
patent: 5994132 (1999-11-01), Chamberlain et al.
patent: 5998205 (1999-12-01), Hallenbeck et al.
patent: 5998598 (1999-12-01), Csaky et al.
patent: 6013638 (2000-01-01), Crystal et al.
patent: 6019978 (2000-02-01), Ertl et al.
patent: 6057158 (2000-05-01), Chamberlain et al.
patent: 6063622 (2000-05-01), Chamberlain et al.
patent: 6066626 (2000-05-01), Yew et al.
patent: 6083750 (2000-07-01), Chamberlain et al.
patent: 6200798 (2001-03-01), Yeh et al.
patent: 6261807 (2001-07-01), Crouzet et al.
patent: 6328958 (2001-12-01), Amalfitano
patent: 6472212 (2002-10-01), Valerio et al.
patent: 6492343 (2002-12-01), Reddy
patent: 2003/0096787 (2003-05-01), Perricaudet et al.
patent: 712304 (1996-04-01), None
patent: WO 90/07573 (1990-07-01), None
patent: WO 94/28152 (1994-12-01), None
patent: WO 96/10088 (1996-04-01), None
patent: WO 96/13597 (1996-05-01), None
patent: WO 98/13499 (1998-04-01), None
patent: WO 98/17783 (1998-04-01), None
US 5,891,715, 04/1999, Haddada et al. (withdrawn)
Rosenberg, “The Immunotherapy of Solid Cancers Based on Cloning the genes Encoding Tumor-Rejection Antigens,”Annu. Rev. Med47: 481-491 (1996).
Slemenda; Nucleic Acids Res.; vol. 18, No. 10, 1990.
Oosterom-Dragon; J. Of Virology; vol. 33, No. 3, pp. 1203-1207, 1980.
Amalfitano et al.: Modification of Adenoviral vectors for use in gene therapy of Duchenne Muscular Dystrophy,The American Journal of Human Genetics57:4 Abstract #1354 Poster Symposium—Session 32 (1995).
Amalfitano et al.: Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors,Proc. Natl. Acad. Sci. USA 93:3352-3356 (1996).
Amalfitano et al.: Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy,Gene Therapy4:258-263 (1997).
Amalfitano et al.: A new class of adenovirus vector: the [E1-, E2b-]Ad vector,Molecular and Cellular Biology of Gene TherapyE:6 24 (1997).
Amalfitano et al.: Production and Characterization of Improved Adenovirus Vectors with the E1, E2b, and E3 Genes Deleted,Journal of Virology72:2 926-933 (1998).
Amalfitano, Editorial,Gene Therapy6:1643-1645 (1999).
Amalfitano et al.: Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-α-glucosidase,Proc. Natl. Acad. Sci. USA96:8861-8866 (1999).
Angeletti et al.: Adenovirus Preterminal Protein Binds to the CAD Enzyme at Active Sites of Viral DNA Replication on the Nuclear Matrix,Journal Of Virology72:4 2896-2904 (1998).
Armentano et al.: Effect of the E4 Region on the Persistence of Transgene Expression from Adenovirus Vectors,Journal Of Virology71:3 2408-2416 (1997).
Bett et al.: An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3,Proc. Natl. Acad. Sci. USA91:8802-8806 (1994).
Brough et al.: Activation of Transgene Expression by Early Region 4 Is Responsible for a High Level of Persistent Transgene Expression from Adenovirus Vectors In Vivo,Journal Of Virology71:12 9206-9213 (1997).
Byrne-et al.; Gene replacement in acid maltase deficiency using DNA viral vectors,Pediatric Research41:19a XP000934188 (1997).
Caravokyri et al.: Constitutive Episomal Expression of Polypeptide IX (pIX) in a 293-Based Cell Line Complements the Deficiency of pIX Mutant Adenovirus Type 5,Journal Of Virology69:11 6627-6633 (1995).
Cepko et al.: Analysis of Ad5-Hexon and 100K is Mutants Using Conformation-Specific Monoclonal Antibodies,Virology129 137-154 (1983).
Chamberlain et.al.: Packaging cells expressing the Adenovirus (Ad) E1, polymerase, and preterminal proteins to allow the growth of a new class of replication defective Ad- vector for use in Duchenne muscular dystrophy (DMD),The American Journal of Human Genetics59:4 Abstract #2196 (1996).
Clemens et al.: in vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes,Gene Therapy3 965-972 (1996).
Cox et al.: Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity,Nature364:725-729 (1993).
Dedieu et al.: Long-Term Gene Delivery into the Livers of Immunocompetent Mice with E I/E4-Defective Adenoviruses,Journal Of Virology71:6 4626-4637 (1997).
Douglas et al.: A system for the propagation of adenoviral vectors with genetically modified receptor specificities,Nature Biotechnology, 17 470-475 (1999).
Elferink et al.: Isolation and characterization of a precursor form of lysosomal α-glucosidase from human urine,Eur. J. Biochem., 139, 489-495 (1984).
Gao et al.: Biology of adenovirus Vectors with E1 and E4 Deletions for Liver-Directed Gene Therapy,Journal Of Virology, 70:12 8934-8943 (1996).
Gilgenkrantz et al.: Transient Expression of Genes Transferred in Vivo into Heart Using First-Generation Adenoviral Vectors: Role of the Immune Response,Human Gene Therapy, 6, 1265-1274 (1995).
Goldman et al.: Transfer of the CFTR Gene to the Lung of Nonhuman Primates with E1-Deleted, E2a-Defective Recombinant Adenoviruses: A Preclinical Toxicology Study,Human Gene Therapy, 6, 839-851 (1995).
Gorziglia et al.: Generation of an Adenovirus Vector Lacking E1, E2a, E3, and All E4 except Open Reading Frame 3,Journal Of Virology, 73:7, 6048-6055 (1999).
Graham et al.: Characteristics of a Human cell Line Transformed by DNA from Human Adenovirus Type 5,J. gen. Virol., 36, 59-72 (1977).
Guo et al.: Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer,Gene Therapy, 3, 802-810 (1996).
Guo et al.: Comparison of Viral Gene-Deleted Adenoviral Vectors With the E1-Deleted Adenoviral Vector in Islets,Transplantation Proceedings, 31, 794 (1999).
Hardy at al.: Construction of Adenovirus Vectors through Cre-loxRecombi
Amalfitano Andrea
Chen Yuan Tsong
Hodges Bradley Lowell
Hu Huimin
Duke University
Myers Bigel & Sibley Sajovec, PA
Sajjadi Fereydoun G
LandOfFree
Deleted adenovirus vectors and methods of making and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Deleted adenovirus vectors and methods of making and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Deleted adenovirus vectors and methods of making and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4211719